Abstract
Cancer treatment has been greatly improved by the combined use of targeted therapies and novel biotechnological methods. Regarding the former, pegylated liposomal doxorubicin (PLD) has a preferential accumulation within cancer tumors, thus having lower toxicity on healthy cells. PLD has been implemented in the targeted treatment of sarcoma, ovarian, breast, and lung cancer. In comparison with conventional doxorubicin, PLD has lower cardiotoxicity and hematotoxicity; however, PLD can induce mucositis and palmo-plantar erythrodysesthesia (PPE, hand-foot syndrome), which limits its use. Therapeutical apheresis is a clinically proven solution against early PLD toxicity without hindering the efficacy of the treatment. The present review summarizes the pharmacokinetics and pharmacodynamics of PLD and the beneficial effects of extracorporeal apheresis on the incidence of PPE during chemoradiotherapy in cancer patients.
Highlights
As a result of their non-selective effects, the use of conventional cytostatics is often influenced by dose-limiting toxicity, the point in which it affects both the tumor and normal cells
A solution to this problem was found in targeted nanoparticle-based drug delivery systems (DDSs) [1,2,3], which allow the delivery of an active substance into the target tissue by altering the pharmacokinetics and toxicological profile of the parent drug [4,5]
The present review presents an overview on the pharmacokinetics and pharmacodynamics of Pegylated Liposomal Doxorubicin (PLD) as doxorubicin
Summary
As a result of their non-selective effects, the use of conventional cytostatics is often influenced by dose-limiting toxicity, the point in which it affects both the tumor and normal cells. A solution to this problem was found in targeted nanoparticle-based drug delivery systems (DDSs) [1,2,3], which allow the delivery of an active substance into the target tissue by altering the pharmacokinetics and toxicological profile of the parent drug [4,5] This targeted distribution is based on both the enhanced permeation and retention effect (EPR) of tumors [6,7,8], an effect that has been known for more than 30 years [9]. The EPR effect is influenced by tumor type and size; in this regard, pancreatic, colon, breast, and stomach. The EPR effect is influenced by tumor type and size; in this regard, cancers have a great capacity for nanoparticle accumulation.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
